EMA Withdrawn: Clopidogrel Sandoz (clopidogrel) — Acino Pharma GmbH

View source ↗

Summary

The EMA indicates withdrawal of Clopidogrel Sandoz (clopidogrel) by Acino Pharma GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction
• Peripheral Vascular Diseases
• Stroke

Drugs mentioned

• Clopidogrel Sandoz (clopidogrel)

Snippet

Status: Withdrawn. Therapeutic area: Peripheral Vascular Diseases;Stroke;Myocardial Infarction. MAH: Acino Pharma GmbH. Decision date: 16/09/2010